1
|
A Pattern to Link Adenosine Signaling, Circadian System, and Potential Final Common Pathway in the Pathogenesis of Major Depressive Disorder. Mol Neurobiol 2022; 59:6713-6723. [PMID: 35999325 PMCID: PMC9525429 DOI: 10.1007/s12035-022-03001-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2022] [Accepted: 08/07/2022] [Indexed: 11/18/2022]
Abstract
Several studies have reported separate roles of adenosine receptors and circadian clockwork in major depressive disorder. While less evidence exists for regulation of the circadian clock by adenosine signaling, a small number of studies have linked the adenosinergic system, the molecular circadian clock, and mood regulation. In this article, we review relevant advances and propose that adenosine receptor signaling, including canonical and other alternative downstream cellular pathways, regulates circadian gene expression, which in turn may underlie the pathogenesis of mood disorders. Moreover, we summarize the convergent point of these signaling pathways and put forward a pattern by which Homer1a expression, regulated by both cAMP-response element binding protein (CREB) and circadian clock genes, may be the final common pathogenetic mechanism in depression.
Collapse
|
2
|
Dubois V, Amokrane K, Crocchiolo R, Fort M, Guillaume N, Kennel A, Michiels S, Ralazamahaleo M, Rouzaire PO, Yakoub-Agha I, Faucher C. [Definition and standardization of histocompatibility requests depending on patient course and donor type: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) and the Francophone Society of Histocompatibility and Immunogenetics (SFHI)]. Bull Cancer 2021; 108:S45-S52. [PMID: 33966883 DOI: 10.1016/j.bulcan.2021.01.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2021] [Revised: 01/27/2021] [Accepted: 01/27/2021] [Indexed: 10/21/2022]
Abstract
Standardization of histocompatibility tests for allogeneic hematopoietic cell transplants, harmonization of information transmitted to clinicians are part of quality improvement and optimization of human and economic resources. New HLA typing technologies provide high-resolution information within a reasonable time frame. Knowledge of high-resolution HLA typing for the patient and their relatives is essential for a better interpretation of compatibilities. HLA-DPB1 typing must be considered in transplant field regardless of the donor type. The benefits of using search and match programs are considerable. It saves time and reduces additional typing costs by providing rapid information about the likelihood to identify a matched unrelated donor. A backup therapy considering alternative cell sources or treatment can therefore be quickly implemented. The importance of knowledge and consideration of patient immunization for donor choice was explored in previous workshops of the SFGM-TC (2018 and 2019). The published recommendations remain applicable. The routine follow-up protocol and in case of desensitization will be detailed here. This harmonization must be accompanied by the standardization of information to be returned to the clinician regarding the donor finding possibilities for the patient. This will guarantee a similar quality level in every center.
Collapse
Affiliation(s)
- Valérie Dubois
- Établissement Français du Sang, laboratoire Histocompatibilité, 69150 Décines, France.
| | - Kahina Amokrane
- Hôpital Saint Louis, laboratoire d'Immunologie Histocompatibilité, 75010 Paris, France
| | - Roberto Crocchiolo
- Servizio di Immunoematologia e Medicina Trasfusionale, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italie
| | - Marylise Fort
- CHU de Toulouse, laboratoire d'Histocompatibilité, Hôpital de RANGUEIL, 31059 Toulouse, France
| | | | - Anne Kennel
- Établissement Français du Sang, laboratoire Histocompatibilité, 42000 Saint-Étienne, France
| | - Sandra Michiels
- Institut Jules Bordet, Département d'Hématologie, Université Libre de Bruxelles, 1000 Bruxelles, Belgique
| | - Mamy Ralazamahaleo
- CHU de Bordeaux, laboratoire d'Immunologie-Immunogénétique, 33076 Bordeaux
| | - Paul-Olivier Rouzaire
- CHU de Clermont-Ferrand, Service d'Histocompatibilité et d'Immunogénétique, Université Clermont Auvergne, EA 7453 CHELTER, 63003 Clermont-Ferrand
| | | | - Catherine Faucher
- Direction prélèvements et greffes de CSH, Direction médicale et scientifique, Agence de la biomédecine, 93212 St-Denis, La Plaine
| |
Collapse
|
3
|
Little AM, Akbarzad-Yousefi A, Anand A, Diaz Burlinson N, Dunn PPJ, Evseeva I, Latham K, Poulton K, Railton D, Vivers S, Wright PA. BSHI guideline: HLA matching and donor selection for haematopoietic progenitor cell transplantation. Int J Immunogenet 2021; 48:75-109. [PMID: 33565720 DOI: 10.1111/iji.12527] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2020] [Revised: 12/29/2020] [Accepted: 12/31/2020] [Indexed: 01/18/2023]
Abstract
A review of the British Society for Histocompatibility and Immunogenetics (BSHI) Guideline 'HLA matching and donor selection for haematopoietic progenitor cell transplantation' published in 2016 was undertaken by a BSHI appointed writing committee. Literature searches were performed and the data extracted were presented as recommendations according to the GRADE nomenclature.
Collapse
Affiliation(s)
- Ann-Margaret Little
- Histocompatibility and Immunogenetics Laboratory, Gartnavel General Hospital, Glasgow, UK.,Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK
| | - Arash Akbarzad-Yousefi
- Histocompatibility and Immunogenetics Laboratory, NHS Blood and Transplant, Newcastle-Upon-Tyne, UK
| | - Arthi Anand
- Histocompatibility and Immunogenetics Laboratory, North West London Pathology, Hammersmith Hospital, London, UK
| | | | - Paul P J Dunn
- Transplant Laboratory University Hospitals of Leicester, Leicester General Hospital, Leicester, UK.,Department of Respiratory Sciences, University of Leicester, Leicester, UK
| | | | - Katy Latham
- Cellular and Molecular Therapies, NHS Blood and Transplant, Bristol, UK
| | - Kay Poulton
- Transplantation Laboratory, Manchester Royal Infirmary, Manchester, UK
| | - Dawn Railton
- Tissue Typing Laboratory, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK
| | | | - Paul A Wright
- Transplantation Laboratory, Manchester Royal Infirmary, Manchester, UK
| |
Collapse
|
4
|
Jana N, Milena V, Eva R, Sara N, Šárka P, Cyril Š, Pietro C, Jana B, Monika B, Evangelista DJ. The formation of a somatic mutation in the HLA-B gene throughout the development of the disease from severe aplastic anaemia to acute myeloid leukaemia. HLA 2019; 94 Suppl 2:30-33. [PMID: 31733047 DOI: 10.1111/tan.13762] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2019] [Revised: 11/13/2019] [Accepted: 11/14/2019] [Indexed: 11/28/2022]
Abstract
We detected a somatic mutation in the HLA-B gene in a Czech hematooncological patient. We followed the development of this somatic mutation during the transition from severe aplastic anaemia through to myelodysplastic syndrome to acute myeloid leukaemia until haploidentical related transplantation. The somatic mutation differs from HLA-B*14:02 in exon 3 resulting in an exchange from cysteine to serine at position 101 of the mature protein. Homology modelling of mutated S101 in HLA-B*14 indicated possible conformational changes, which might also result in an aberrant expression. The assumption is that somatic mutation arose as a possible result of a selection mediated by a protective immune response against leukaemia.
Collapse
Affiliation(s)
- Neupauerová Jana
- Institute of Hematology and Blood Transfusion, Hematology and Blood Transfusion, Prague, Czech Republic
| | - Vraná Milena
- Institute of Hematology and Blood Transfusion, Hematology and Blood Transfusion, Prague, Czech Republic
| | - Ratajová Eva
- Institute of Hematology and Blood Transfusion, Hematology and Blood Transfusion, Prague, Czech Republic
| | - Nazarova Sara
- Institute of Hematology and Blood Transfusion, Hematology and Blood Transfusion, Prague, Czech Republic
| | - Půbalová Šárka
- Institute of Hematology and Blood Transfusion, Hematology and Blood Transfusion, Prague, Czech Republic
| | - Šálek Cyril
- Institute of Hematology and Blood Transfusion, Hematology and Blood Transfusion, Prague, Czech Republic
| | - Crivello Pietro
- Institute of Experimental Cellular Therapy, University Hospital Essen, Essen, Germany
| | - Březinová Jana
- Institute of Hematology and Blood Transfusion, Hematology and Blood Transfusion, Prague, Czech Republic
| | - Beličková Monika
- Institute of Hematology and Blood Transfusion, Hematology and Blood Transfusion, Prague, Czech Republic
| | - Dyr J Evangelista
- Institute of Hematology and Blood Transfusion, Hematology and Blood Transfusion, Prague, Czech Republic
| |
Collapse
|
5
|
Balas A, Planelles D, Goterris R, Rodríguez-Cebriá M, Vicario JL. Somatic mutation in the two HLA-B genes of a patient with acute myelogenous leukemia. HLA 2019; 94:360-364. [PMID: 31338977 DOI: 10.1111/tan.13640] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2019] [Revised: 06/24/2019] [Accepted: 07/22/2019] [Indexed: 12/28/2022]
Abstract
In this report, we describe a case of somatic mutations in the two HLA-B genes in a patient with acute myelogenous leukemia. The HLA-B*15:01 allele showed an insertion of two nucleotides within exon 2 leading to a premature stop codon. HLA-B*40:01 showed one nucleotide substitution within exon 3, identical to that described for B*15:258N. The restriction of these mutations in leukemic cells was confirmed in patient's samples from buccal epithelial cells and hematopoietic cells obtained when the patient was in remission. The clinical significance of somatic HLA mutations in cancer seems to be associated with escape from immune surveillance and clonal evolution. The analysis of possible mutations in HLA genes of tumor cells would be valuable information for the outcome of the disease and stem cell donor selection.
Collapse
Affiliation(s)
- Antonio Balas
- Histocompatibilidad, Centro de Transfusión de la Comunidad de Madrid, Madrid, Spain
| | - Dolores Planelles
- Histocompatibilidad, Centro de Transfusión de la Comunidad Valenciana, Valencia, Spain
| | - Rosa Goterris
- Hematología, Hospital Clínico Universitario de Valencia, Valencia, Spain
| | | | - José L Vicario
- Histocompatibilidad, Centro de Transfusión de la Comunidad de Madrid, Madrid, Spain
| |
Collapse
|
6
|
Park S, Jeong TD, Mun YC, Seo D, Im J, Huh J. Somatic mutation of
HLA‐DRB1*04:03
in a patient with myelodysplastic syndrome at diagnosis. HLA 2019; 93:216-219. [DOI: 10.1111/tan.13490] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2018] [Revised: 02/08/2019] [Accepted: 02/12/2019] [Indexed: 12/01/2022]
Affiliation(s)
- Sholhui Park
- Department of Laboratory MedicineEwha Womans University, College of Medicine Seoul South Korea
| | - Tae D. Jeong
- Department of Laboratory MedicineEwha Womans University, College of Medicine Seoul South Korea
| | - Yeung C. Mun
- Department of Internal MedicineEwha Womans University, College of Medicine Seoul South Korea
| | - Dongchun Seo
- Department of Laboratory MedicineEwha Womans University, College of Medicine Seoul South Korea
| | - Jisu Im
- Research and Development TeamBiowithus Life Science Institute Seoul South Korea
| | - Jungwon Huh
- Department of Laboratory MedicineEwha Womans University, College of Medicine Seoul South Korea
| |
Collapse
|
7
|
Königova N, Skoumalova I, Onderkova J, Ambruzova Z, Szotkowski T, Koristek Z, Maluskova A, Raida L, Mrazek F. HLA-B gene somatic insertion/deletion mutations in patients with acute myelogenous leukaemia. Int J Immunogenet 2018; 45:323-328. [DOI: 10.1111/iji.12393] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2018] [Revised: 05/25/2018] [Accepted: 06/25/2018] [Indexed: 02/06/2023]
Affiliation(s)
- Nikola Königova
- Department of Immunology; University Hospital; Olomouc Czech Republic
- Faculty of Medicine and Dentistry; Palacky University; Olomouc Czech Republic
| | - Ivana Skoumalova
- Faculty of Medicine and Dentistry; Palacky University; Olomouc Czech Republic
- Department of Haemato-oncology; University Hospital; Olomouc Czech Republic
| | - Jana Onderkova
- Department of Immunology; University Hospital; Olomouc Czech Republic
- Faculty of Medicine and Dentistry; Palacky University; Olomouc Czech Republic
| | - Zuzana Ambruzova
- Department of Immunology; University Hospital; Olomouc Czech Republic
- Faculty of Medicine and Dentistry; Palacky University; Olomouc Czech Republic
| | - Tomas Szotkowski
- Faculty of Medicine and Dentistry; Palacky University; Olomouc Czech Republic
- Department of Haemato-oncology; University Hospital; Olomouc Czech Republic
| | - Zdenek Koristek
- Department of Haemato-oncology; University Hospital; Ostrava Czech Republic
- Medical Faculty; Ostrava University; Ostrava Czech Republic
| | | | - Ludek Raida
- Faculty of Medicine and Dentistry; Palacky University; Olomouc Czech Republic
- Department of Haemato-oncology; University Hospital; Olomouc Czech Republic
| | - Frantisek Mrazek
- Department of Immunology; University Hospital; Olomouc Czech Republic
- Faculty of Medicine and Dentistry; Palacky University; Olomouc Czech Republic
| |
Collapse
|
8
|
Identification of an HLA class I allele closely involved in the autoantigen presentation in acquired aplastic anemia. Blood 2017; 129:2908-2916. [DOI: 10.1182/blood-2016-11-752378] [Citation(s) in RCA: 55] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2016] [Accepted: 02/20/2017] [Indexed: 12/26/2022] Open
Abstract
Key Points
Somatic mutations of HLA-B*40:02 are very frequently detected in granulocyte of patients with acquired aplastic anemia. Antigen presentation via HLA-B4002 may play a critical role in the pathophysiology of acquired aplastic anemia.
Collapse
|
9
|
Jeong TD, Mun YC, Chung HS, Seo D, Im J, Huh J. Novel deletion mutation of HLA-B*40:02 gene in acquired aplastic anemia. HLA 2016; 89:47-51. [PMID: 28025876 DOI: 10.1111/tan.12943] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2016] [Revised: 10/31/2016] [Accepted: 11/17/2016] [Indexed: 01/03/2023]
Abstract
Despite prevalence of clonal evolution in patients with aplastic anemia (AA), somatic mutation of human leukocyte antigen (HLA) gene is rarely reported. Herein, we reported a case of acquired AA (aAA) harboring a new four-base-pair deletion mutation within exon 4 of HLA-B*40:02 leading to frameshift and premature stop codon. The HLA-B*40:02 mutant allele was detected in the patient's peripheral blood sample not in patient's buccal epithelial cells. The patient received allogenic hematopoietic stem cell transplantation (HSCT) from HLA-matched sibling donor. On day 30 after HSCT, the mutant HLA allele was not detected by high-resolution sequence-based HLA typing. Serial chimerism analyses showed mixed chimeric status indicative of coexisting donor and recipient hematopoietic cells. Our data could provide additional support in view of pathophysiology of aAA that somatic mutation of HLA-B*40:02 allele is one of the possible origin of clonal escape to evade immune attack in patient with aAA.
Collapse
Affiliation(s)
- T-D Jeong
- Department of Laboratory Medicine, Ewha Womans University School of Medicine, Seoul, Korea
| | - Y-C Mun
- Division of Hematology & Oncology, Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, Korea
| | - H-S Chung
- Department of Laboratory Medicine, Ewha Womans University School of Medicine, Seoul, Korea
| | - D Seo
- Department of Laboratory Medicine, Ewha Womans University School of Medicine, Seoul, Korea
| | - J Im
- Research and Development Team, Biowithus Life Science Institute, Seoul, Korea
| | - J Huh
- Department of Laboratory Medicine, Ewha Womans University School of Medicine, Seoul, Korea
| |
Collapse
|
10
|
Ramírez E, Bellón T, Tong HY, Borobia AM, de Abajo FJ, Lerma V, Moreno Hidalgo MA, Castañer JL, Cabañas R, Fiandor A, González-Ramos J, Herranz P, Cachafeiro L, González-Herrada C, González O, Aramburu JA, Laosa O, Hernández R, Carcas AJ, Frías J. Significant HLA class I type associations with aromatic antiepileptic drug (AED)-induced SJS/TEN are different from those found for the same AED-induced DRESS in the Spanish population. Pharmacol Res 2016; 115:168-178. [PMID: 27888155 DOI: 10.1016/j.phrs.2016.11.027] [Citation(s) in RCA: 50] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/20/2016] [Revised: 11/21/2016] [Accepted: 11/21/2016] [Indexed: 12/17/2022]
Abstract
Aromatic antiepileptic drugs (AEDs) are among the drugs most frequently involved in severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reactions with eosinophilia and systemic symptoms (DRESS). This study investigated the associations between the genetic polymorphisms of HLA class-I and AED-induced SCARs in the Spanish population. HLA class-I genotypes were determined in AED (phenytoin[PHT],lamotrigine[LTG],carbamazepine[CBZ],phenobarbital[PB])-induced SJS/TEN (n=15) or DRESS (n=12) cases included in the Spanish SCAR registry, PIELenRed. There were 3 control groups: (A)tolerant to a single AED, (B)tolerant to any AED, and (C)Spanish population controls. For SJS/TEN, concomitant HLA-A*02:01/Cw15:02 alleles were significantly associated with PHT-cases compared to control groups B and C [(B)odds ratio(OR):14.75, p=0.009;(C)OR:27.50, p<0.001], and were close to significance with respect to control group A (p=0.060). The genotype frequency of the HLA-B*38:01 was significantly associated with PHT-LTG-cases compared with the 3 groups of controls [(A)OR:12.86, p=0.012;(B)OR:13.81; p=0.002;(C)OR:14.35, p<0.001], and with LTG-cases [(A)OR:147.00, p=0.001;(B)OR:115.00, p<0.001;(C)OR:124.70, p<0.001]. We found the HLA-B*15:02 allele in a Spanish Romani patient with a CBZ-case. The HLA-A*11:01 was significantly associated with CBZ-cases [(A)OR:63.89, p=0.002;(B)OR:36.33, p=0.005;(C)OR:28.29, p=0.007]. For DRESS, the HLA-A*24:02 genotype frequency was statistically significant in the PHT-LTG-cases [(A)OR:22.56, p=0.003;(B)OR:23.50. p=0.001; (C)OR:33.25, p<0.001], and in the LTG-cases [(A),OR:49.00, p=0.015;(B)OR:27.77, p=0.005; (C)OR:34.53, p=0.002]. HLA-A*31:01 was significantly associated with the CBZ-cases [(A)OR:22.00, p=0.047;(B)OR:29.50, p=0.033;(C)OR:35.14, p=0.006]. In conclusion, we identified several significant genetic risk factors for the first time in the Spanish Caucasian population: HLA-A*02:01/Cw*15:02 combination as a risk factor for PHT-induced SJS/TEN, HLA-B*38:01 for LTG- and PHT- induced SJS/TEN, HLA-A*11:01 for CBZ-induced SJS/TEN, and HLA-A*24:02 for LTG- and PHT- induced DRESS. The strong association between HLA*31:01 and CBZ-DRESS in Europeans was confirmed in this study.
Collapse
Affiliation(s)
- Elena Ramírez
- Department of Clinical Pharmacology, La Paz University Hospital-Carlos III, IdiPAZ, School of Medicine, Autonomous University of Madrid, Madrid, Spain.
| | - Teresa Bellón
- Institute for Health Research, La Paz University Hospital, IdiPAZ, Madrid, Spain
| | - Hoi Y Tong
- Department of Clinical Pharmacology, La Paz University Hospital-Carlos III, IdiPAZ, School of Medicine, Autonomous University of Madrid, Madrid, Spain
| | - Alberto M Borobia
- Department of Clinical Pharmacology, La Paz University Hospital-Carlos III, IdiPAZ, School of Medicine, Autonomous University of Madrid, Madrid, Spain
| | - Francisco J de Abajo
- Clinical Pharmacology Unit, Príncipe de Asturias University Hospital, Department of Biomedical Sciences (Pharmacology), University of Alcalá, Madrid, Spain
| | - Victoria Lerma
- Clinical Pharmacology Unit, Príncipe de Asturias University Hospital, Department of Biomedical Sciences (Pharmacology), University of Alcalá, Madrid, Spain
| | | | - José L Castañer
- Immunology Department, Ramón y Cajal University Hospital, Madrid, Spain
| | - Rosario Cabañas
- Allergy Department, La Paz University Hospital-Carlos III, IdiPAZ, Madrid, Spain
| | - Ana Fiandor
- Allergy Department, La Paz University Hospital-Carlos III, IdiPAZ, Madrid, Spain
| | | | - Pedro Herranz
- Dermatology Department, La Paz University Hospital-Carlos III, IdiPAZ, Madrid, Spain
| | - Lucía Cachafeiro
- Intensive Care Department, La Paz University Hospital-Carlos III, IdiPAZ, Madrid, Spain
| | | | - Olga González
- Dermatology Department, Getafe University Hospital, Madrid, Spain
| | - José A Aramburu
- Pathological Anatomy Department, Getafe University Hospital, Madrid, Spain
| | - Olga Laosa
- Clinical Pharmacology Unit, Geriatric Department, Getafe University Hospital, Madrid, Spain
| | - Rafael Hernández
- Department of Clinical Pharmacology, La Paz University Hospital-Carlos III, IdiPAZ, School of Medicine, Autonomous University of Madrid, Madrid, Spain
| | - Antonio J Carcas
- Department of Clinical Pharmacology, La Paz University Hospital-Carlos III, IdiPAZ, School of Medicine, Autonomous University of Madrid, Madrid, Spain
| | - Jesús Frías
- Department of Clinical Pharmacology, La Paz University Hospital-Carlos III, IdiPAZ, School of Medicine, Autonomous University of Madrid, Madrid, Spain.
| |
Collapse
|
11
|
Little AM, Green A, Harvey J, Hemmatpour S, Latham K, Marsh SGE, Poulton K, Sage D. BSHI Guideline: HLA matching and donor selection for haematopoietic progenitor cell transplantation. Int J Immunogenet 2016; 43:263-86. [DOI: 10.1111/iji.12282] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2016] [Revised: 05/06/2016] [Accepted: 06/06/2016] [Indexed: 12/29/2022]
Affiliation(s)
- A-M. Little
- Histocompatibility and Immunogenetics Laboratory; Gartnavel General Hospital; Glasgow UK
- Institute of Infection, Immunity and Inflammation; College of Medical, Veterinary and Life Sciences; University of Glasgow; Glasgow UK
| | - A. Green
- Histocompatibility and Immunogenetics Laboratory; NHS Blood and Transplant; Filton UK
| | - J. Harvey
- Histocompatibility and Immunogenetics Laboratory; NHS Blood and Transplant; Filton UK
| | - S. Hemmatpour
- Histocompatibility and Immunogenetics Laboratory; NHS Blood and Transplant; London Tooting UK
| | - K. Latham
- Anthony Nolan Research Institute; Royal Free Hospital; London UK
| | - S. G. E. Marsh
- Anthony Nolan Research Institute; Royal Free Hospital; London UK
- Cancer Institute; University College London; London UK
| | - K. Poulton
- Transplantation Laboratory; Manchester Royal Infirmary; Manchester UK
- British Society for Histocompatibility & Immunogenetics
| | - D. Sage
- Histocompatibility and Immunogenetics Laboratory; NHS Blood and Transplant; London Tooting UK
| |
Collapse
|
12
|
Planelles D, Balas A, Gil C, Muñoz C, Rodríguez-Cebriá M, Vicario JL. Somatic mutation in the HLA-B gene of a patient with acute myelogenous leukaemia. HLA 2016; 88:35-7. [DOI: 10.1111/tan.12830] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2016] [Revised: 05/25/2016] [Accepted: 05/27/2016] [Indexed: 12/30/2022]
Affiliation(s)
- D. Planelles
- Histocompatibilidad; Centro de Transfusión de la Comunidad Valenciana; Valencia Spain
| | - A. Balas
- Histocompatibilidad; Centro de Transfusión de la Comunidad de Madrid; Madrid Spain
| | - C. Gil
- Hematología; Hospital General Universitario de Alicante; Alicante Spain
| | - C. Muñoz
- Inmunología; Hospital General Universitario de Alicante; Alicante Spain
| | - M. Rodríguez-Cebriá
- Histocompatibilidad; Centro de Transfusión de la Comunidad Valenciana; Valencia Spain
| | - J. L. Vicario
- Histocompatibilidad; Centro de Transfusión de la Comunidad de Madrid; Madrid Spain
| |
Collapse
|